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Calcimimetics, parathyroid 
hormone, and vascular 
calcification in chronic  
kidney disease
Giorgio Coen1
Vascular calcification (VC) occurs frequently in chronic kidney disease, 
contributing to cardiovascular mortality. Numerous risk factors have 
been identified, including renal osteodystrophy and bone turnover, 
with low turnover as a main determinant. Other reports support 
high turnover as a factor in VC. Calcimimetics, which lower serum 
parathyroid hormone, and parathyroidectomy each prevented 
VC induced by five-sixths nephrectomy in rats. These results favor 
increased bone turnover due to hyperparathyroidism, instead of low 
turnover, as a factor in VC in uremia.
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Vascular calcification (VC) in uremic 
patients has become an important area 
of research in the past decade and has 
been related, at least in part, to the fre-
quent occurrence of cardiovascular death 
in patients with chronic kidney disease. 
It is now known that most patients with 
various degrees of renal insufficiency will 
never reach dialysis treatment, as they 
are destined to die before end-stage renal 
disease as a result of cardiovascular dis-
ease. One important factor in cardiovas-
cular death in uremic subjects has been 
recognized in arterial calcifications and 
stiffening. Calcification of the arteries is 
due to calcium deposits in atherosclerotic 
plaques of the intima and in the media 
layer. Rigidity of main arteries is a cause 
of myocardial hypertrophy and dilatation 
and is due partly to calcification, but also 
to change in the structure of the arterial 
wall with loss of the elastic lamina.
The study of arterial and coronary 
calcification has been improved by the 
introduction of imaging techniques such 
as electron beam computed tomography 
and, lately, multislice computed tom-
ography. Many risk factors for arterial 
calcium deposits have been identified. 
Among these are age, dialysis vintage, and 
male gender. Increased serum phosphate 
levels have been proposed as an impor-
tant factor in cardiovascular mortality in 
hemodialysis patients. At the same time, 
increased serum phosphate was found to 
be an important risk factor for arterial 
calcifications. Giachelli et al.1 have pro-
vided evidence that hyper phosphatemia 
may affect vascular smooth muscle cells, 
promoting their differentiation into 
osteo blast-like cells, which are able to 
synthesize a number of proteins that favor 
the calcification of the artery. Among 
these, collagen type I, osteocalcin, osteo-
pontin, and alkaline phosphatase are of 
paramount importance. Therefore, the 
occurrence of arterial calcification in 
uremic patients is now thought of not as 
due to a passive precipitation mechanism 
but as a well-structured event in which 
cell activity and differentiation are able to 
induce a process resembling the calcifi-
cation occurring in bone tissue. Further 
studies have provided more information 
on the complexity of the equilibrium 
between calcification-favoring factors, 
such as plasma supersaturation of cal-
cium and phosphate, and inhibitory fac-
tors, able to prevent calcium deposits in 
the arteries. Several animal models have 
shown the importance of fetuin-A, matrix 
GLA protein, and osteoprotegerin in pre-
venting calcium deposits and how these 
factors can be modulated by other condi-
tions, such as inflammatory states, mal-
nutrition, and lipoprotein derangements. 
Additional risk factors for vascular calci-
fications have been hypothesized, such as 
bone status of uremic patients, in whom 
different types of bone disease, ranging 
from low to increased turnover, may be 
present (Figure 1). Even in non-uremic 
patients, a possible linkage exists between 
bone and vascular tissue, as an associa-
tion was found between osteoporosis and 
vascular calcium deposits.
The relationship between bone turn-
over and VC in hemodialysis patients 
is still a matter of controversy. The cur-
rent opinion is that an association exists 
between low bone turnover and increased 
risk of VC in hemodialysis patients. This 
opinion is supported by the concept 
of bone tissue as a calcium- and phos-
phate-buffering compartment. Restric-
tion of this compartment in adynamic 
bone has been studied and confirmed by 
Kurz et al.2 with calcium tracers. How-
ever, clear evidence of this inverse asso-
ciation between bone turnover and VC 
in uremic subjects is lacking. The major 
contrib ution was provided by the study 
by London et al.,3 based on a cohort 
of dialysis patients subjected to bone 
biopsy for histo morphometric study 
and semiquantitative evaluation of arte-
rial calcium deposits by means of ultra-
sonography and X-rays of main arteries. 
The study revealed evidence of low bone 
activity and adynamic bone in patients 
with major arterial calcium deposits. 
However, the parameter bone formation 
rate (BFR/BS), the best indicator of bone 
turnover, was not evaluated. Moreover, 
this interesting report was questionable 
because a large number of previously 
parathyroidectomized patients were 
part of the cohort, with calcifications 
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presumably formed before parathyroid-
ectomy. In addition, many of the patients 
were severely aluminium loaded, with 
consequent decreased bone activity and 
lower serum parathyroid hormone (PTH) 
levels. Patients with more severe calcium 
deposits had received more calcium car-
bonate as a chelating agent. Therefore, low 
bone turnover may have been caused by 
excessive calcium loads, rather than alu-
minium deposition, triggering vascular 
calcium deposits.
In contrast, experimental studies in rats 
have shown the importance of increased 
bone turnover as a risk factor for VC in 
uremia. Price et al.4 have shown in uremic 
rats that high bone turnover is accompa-
nied by a wider extent of medial artery 
calcification; this can be prevented by a 
dose of ibandronate, which inhibits bone 
resorption. The authors concluded that 
medial artery calcification is linked to 
bone resorption. There is a fetuin–mineral 
complex in the blood of rats in which 
extensive calcification of the artery media 
is induced. This complex is generated in 
the bone remodeling compartment and 
is inhibited by bispho sphonates or osteo-
protegerin. However, the existence of this 
complex in humans has so far not been 
confirmed.
Another interesting experimental 
study, by Neves et al.,5 explored the possi-
ble contribution of PTH to cardiovascular 
calcifications in uremic rats. Parathyroid-
ectomy was performed in five-sixths-
nephrectomized rats and a continuous 
infusion of PTH started. All rats on PTH 
replacement developed extensive aortic 
calcification, and some animals also 
presented coronary calcifications. These 
findings were apparently unrelated to 
differences in dietary phosphorus and 
to the serum levels of calcium and phos-
phate. Calcifications were also observed 
in rats with normal levels of these ions. 
The authors suggested that high PTH 
levels induce elevated bone turnover and 
medial calcification, as in Mönckeberg’s 
sclerosis. In line with these results are the 
data published by Coen et al.6 Among 197 
patients on hemodialysis, multislice com-
puted tomography showed a significant 
increase in coronary calcification scores 
in the patients with high serum PTH lev-
els, known to be associated with elevated 
bone turnover, while in the patients with 
lower PTH values (0–150 pg/ml), mainly 
associated with low bone turnover and 
adynamic bone, calcification scores were 
higher than normal but significantly 
lower than in the groups with high serum 
PTH levels.
In the study by Kawata et al.7 (this 
issue), the matter of the rate of bone 
turnover as a possible factor in VC in the 
uremic subject has been dealt with by a 
different approach. This experimental 
study is an important contribution to a 
better insight into the mechanism of VC, 
despite the limits in interpreting animal 
models and translating their conclusions 
to clinical understanding. The authors 
examined the effects of calcimimetic 
administration on aortic and heart cal-
cification in five-sixths-nephrectomized 
rats, on a diet sufficiently rich in 
phosphate and calcium. The calcimimetic 
drug was administered for 41 days, and 
the results were compared with those in 
control nephrectomized rats not receiv-
ing the drug. In addition, to further 
elucidate the role of PTH, Kawata et al. 
studied the effects of parathyroidectomy 
on the development of aortic and heart 
calcification. Both groups of animals with 
suppression of serum PTH levels, due 
to calcimimetic administration or total 
parathyroidectomy, did not develop VC, 
whereas calcifications were found in con-
trol animals. A decrease of bone turnover 
associated with calcimimetic adminis-
tration was also suggested by the fall in 
serum osteocalcin. In nephrectomized 
cinacalcet-treated rats, there was no 
mRNA expression of osteoblastic mark-
ers such as osteocalcin, osteopontin, and 
RunX2, in contrast to nephrectomized 
vehicle-treated rats. A mild reduction 
in serum phosphate and CaxP product 
induced by cinacalcet administration or 
by parathyroidectomy could have played 
a role in the suppression of VC. The rats 
did not receive vitamin D and calcitriol, 
and their serum levels were not consid-
ered to be calcification factors. In other 
studies,8 calcimimetics were found to 
counteract the VC effect of calcitriol. 
Calcitriol administration to uremic 
rats induced VC in spite of a decrease 
of serum PTH levels. This calcitriol-
induced calcification was prevented by 
the administration of calcimimetics. It is 
worth mentioning that a clinical control 
trial to evaluate cinacalcet or standard 
therapy with VC as primary end point 
is in progress.
A possibility remains that calcimimetics 
might have a direct protective effect on vas-
cular tissue against calcification induced 
either by calcitriol and vitamin D receptor 
activators or by the uremic state itself, act-
ing independently of the suppressed bone 
turnover. A study by Molostvov et al.9 
evaluated the expression of CaSR mRNA 
and protein in human aortic smooth mus-
cle and endothelial cells in large and small 
arteries. The expression of the CaSR was 
lower in end-stage renal disease. There-
fore, a direct effect of calcimimetics on 
the arterial wall inducing protection from 
the calcification process cannot be ruled 
out. Further studies in this direction are 
required.
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Figure 1 | Mechanisms of vascular calcification in chronic kidney disease. MGP, matrix GLA 
protein; OPG, osteoprotegerin.
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Extracorporeal removal of toxins
Pallavi K. Tyagi1, James F. Winchester1 and Donald A. Feinfeld1
Holubek et al. reviewed data on extracorporeal removal (ECR) of toxins 
from the Toxic Exposure Surveillance System (TESS) from 1985 to 2005. 
Hemodialysis use increased, but hemoperfusion nearly disappeared. 
Lithium, ethylene glycol, salicylate, and, increasingly, acetaminophen still 
often necessitate hemodialysis; ECR for theophylline has disappeared. 
TESS data do not separate continuous renal replacement therapy from 
hemodialysis, and not all poisonings were reported in this system. 
Nonetheless, these trends are useful to the nephrology community.
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Extracorporeal removal (ECR) techniques 
used for clearance of toxins can be a criti-
cal step in the management of chemical 
or drug poisoning. The use of these tech-
niques for removal of toxins can be justi-
fied if there is evidence of severe toxicity 
and if the total-body elimination of the 
toxin can be increased by 30% or more 
by the extracorporeal technique.1 Large 
randomized controlled trials of ECR in 
toxicology are hard to come by and, for 
obvious reasons, difficult to perform. 
Specific extracorporeal techniques and 
their indications remain a matter of 
debate. Application of extracorporeal 
modalities requires a thorough knowledge 
of drug pharmacokinetics and of the tech-
niques available. The technology of choice 
for the removal of a particular toxin, how-
ever, may not be immediately available to 
physicians in clinical practice.
Holubek et al.2 (this issue) describe 
trends in the use of ECR for removal 
of toxins in the United States over a 
21-year period of poison-center data 
recorded in the Toxic Exposure Surveil-
lance System (TESS) database from 1985 
to 2005. TESS is a uniform data set of 
cases reported from poison centers in 
the United States. Categories of infor-
mation include the patient, caller, route 
of exposure, substance or substances, 
clinical picture, treatment, and medical 
outcomes. The trend was an increase in 
hemodialysis (HD) use with a decrease 
in hemoperfusion (HP) over the final 10 
years. This may be attributed to a change 
in the technology itself as well as a change 
in the profiles of drugs causing overdose. 
Improvement in HD technologies over 
the years, with use of newer synthetic 
membranes at greater blood flow rates, 
has resulted in drug elimination rates 
similar to that achieved through HP.3 HP 
cartridges are expensive and have limited 
shelf life, and some require sterilization. 
It is technically more difficult to perform, 
cannot correct the acid–base fluid and 
electrolyte abnormalities associated with 
intoxications, and can cause thrombocy-
topenia, leukopenia, and hypocalcemia. 
According to TESS data from 2004, only 
27 of the almost 2.5 million exposures 
reported to United States poison control 
centers were managed with charcoal HP.4 
Shalkham et al. reported the availability 
of charcoal HP cartridges in only approx-
imately one-third of hospitals receiving 
emergency patients in New York City, 
and only three in-hospital HD units had 
performed HP in the past five years, on 
three cases.5 The use of theophylline and 
barbiturate drugs, which were tradition-
ally removed by HP, has declined, lead-
ing to a decline in the use of HP for their 
elimination.6
The role of continuous renal replace-
ment therapy (CRRT), available since the 
late 1970s, in the treatment of poisoning 
is still under debate and is not currently 
reported in the TESS database. The use of 
continuous veno-venous hemofiltration 
(CVVH) and continuous veno-venous 
hemodiafiltration (CVVHD) have been 
reported in poisonings with salicylates, 
barium, lithium, carbamazepine, phe-
nobarbital, methanol, iodine, pilsicain-
ide, mercury, metformin, valproic acid, 
and tetramine. CVVH and CVVHD are 
considered continuous therapies because 
they are applied for a longer time (24–48 
hours) than HD (usually 4–6 hours). 
An advantage of CVVH and CVVHD 
is that they are better tolerated than HD 
in hemodynamically unstable patients. 
CVVH achieves solute clearance by con-
vection (solvent drag effect) through the 
membrane, with pore dimensions larger 
